11 recruiting, 7 unknown, 6 completed, 2 active not recruiting. 31 Phase 2, 6 Phase 1.
Follow Hepatocellular Carcinoma Non-resectable: new trials by email Literature Review of Hepatocellular Carcinoma Non-resectable trials Research Report on Hepatocellular Carcinoma Non-resectable
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis Selective Internal Radiotherapy, Tremelimumab, Durvalumab - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Center Eugene Marquis | 80 | 2026-02-25 | 2026-05-05 |
| Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy Adebrelimab + Apatinib - Hepatocellular Carcinoma Non-resectable | Phase 2 | Not yet recruiting | Song Peng | 47 | 2025-09-01 | 2025-09-25 |
| Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC Lenvatinib plus SIRT, Lenvatinib - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 78 | 2025-04-01 | 2025-04-29 |
| Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT LEN+SIN+DEB-TACE+HAIC, LEN+SIN+DEB-TACE - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 320 | 2025-04-01 | 2026-08-11 |
| Y-90 SIRT for Unresectable HCC Larger Than 7cm SIRT - Hepatocellular Carcinoma Non-Resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 33 | 2024-12-01 | 2025-01-28 |
| A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab Cabozantinib - Hepatocellular Carcinoma Non-resectable | Phase 2 | Not yet recruiting | Chulalongkorn University | 40 | 2024-08-01 | 2024-08-02 |
| Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma Lenvatinib - Hepatocellular Carcinoma Non-resectable | Phase 1 / Phase 2 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 25 | 2024-07-10 | 2025-04-07 |
| DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC DEB-TACE+HAIC, DEB-TACE - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 130 | 2024-05-01 | 2025-02-20 |
| Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC Sin-Bev-SIRT - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 23 | 2024-05-01 | 2024-05-07 |
| Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） - Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-03-14 | 2024-04-19 |
| mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria mFOLFOX7 combined with Camrelizumab and apatinib - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 29 | 2024-02-17 | 2024-09-23 |
| Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2) Selective Internal Radiation Therapy with 188Re-SSS lipiodol - Hepatocellular Carcinoma Non-resectable | Phase 2 | Terminated | Center Eugene Marquis | 16 | 2024-02-14 | 2026-07-02 |
| HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma Hepatic arterial infusion chemotherapy (HAIC-FOLFOX), Lenvatinib, Cadonilimab - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Tongji Hospital | 36 | 2023-12-30 | 2026-08-26 |
| Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma Atezolizumab, Bevacizumab, Proton radiotherapy - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Chang Gung Memorial Hospital | 45 | 2023-11-16 | 2026-03-20 |
| Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Cadonilimab, Stereotactic radiotherapy, Renvatinib - Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus | Phase 1 / Phase 2 | Unknown | First Affiliated Hospital of Guangxi Medical University | 30 | 2023-02-02 | 2023-09-15 |
| Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 2 | Recruiting | Asan Medical Center | 138 | 2022-10-22 | 2025-02-21 |
| A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two - Hepatocellular Carcinoma, Solid Tumor | Phase 1 / Phase 2 | Terminated | Omega Therapeutics | 24 | 2022-08-19 | 2025-02-03 |
| Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma Fluorine-18 fluorocholine - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Queen's Medical Center | 80 | 2022-03-28 | 2026-08-12 |
| Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC Regorafenib + sintilimab, Regorafenib - Hepatocellular Carcinoma Non-resectable | Phase 2 | Unknown | Second Affiliated Hospital of Guangzhou Medical University | 166 | 2021-01-09 | 2022-11-10 |
| Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC Tremelimumab, Durvalumab, Y-90 SIRT - Hepatocellular Carcinoma Non-resectable, HCC | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 55 | 2020-12-15 | 2026-06-23 |
Showing 20 of 31. Sign in to see all of them.
Carcinoma, Hepatocellular (20) · Liver Neoplasms (2) · Disease (1)
Adenocarcinoma (20) · Carcinoma (20) · Digestive System Diseases (20) · Digestive System Neoplasms (20) · Liver Diseases (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Neoplasms by Site (20) · Neoplasms, Glandular and Epithelial (20) · Liver Neoplasms (18) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
lenvatinib (6) · Bevacizumab (3) · atezolizumab (3) · camrelizumab (3) · Fluorouracil (2) · Sirtuins (2) · Sorafenib (2) · apatinib (2) · cabozantinib (2) · durvalumab (2) · sintilimab (2) · tremelimumab (2) · 130-nm albumin-bound paclitaxel (1) · ALT-803 (1) · Capecitabine (1)
Second Affiliated Hospital of Guangzhou Medical University (8) · Center Eugene Marquis (2) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · CbsBioscience (1) · Chang Gung Memorial Hospital (1) · Chulalongkorn University (1) · First Affiliated Hospital of Guangxi Medical University (1) · ImmunityBio, Inc. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Ludwig-Maximilians - University of Munich (1) · Omega Therapeutics (1) · Queen's Medical Center (1)
China (17) · France (3) · Germany (3) · South Korea (3) · United States (3) · Taiwan (2) · Hong Kong (1) · Netherlands (1) · Singapore (1)
Kangshun Zhu, Dr. (4) · Arndt Vogel, Prof. Dr. (2) · Etienne Garin, MD PHD (2) · Salah-Eddin Al-Batran, Prof. Dr. (2) · Han Dr. Gao (1) · Ju Hyun Shim (1) · Krittaya Korphaisarn, M.D. (1) · Liangrong Shi, M.D. (1) · Marnix G. Lam, MD, PhD (1) · Mingyue Cai, Dr. (1) · Nuttapong Ngamphaiboon, M.D. (1) · Sandi A Kwee, MD, PhD (1) · Si Hyun Bae, MD., PhD. (1) · Suebpong Tanasanvimon, M.D. (1)
PMID 32112738, PMID 35081747, PMID 35101942, PMID 36852452, PMID 38291865, PMID 39786516, PMID 41293180, PMID 42682622
2019 (3), R01CA262460 (1)